HOW THE DOCTOR CAN COUNTER COMMERCIAL BIAS IN THE DISSEMINATION OF PHARMACOTHERAPEUTIC KNOWLEDGE
- 1 September 2002
- journal article
- editorial
- Published by Wolters Kluwer Health in Journal of Nervous & Mental Disease
- Vol. 190 (9) , 593-596
- https://doi.org/10.1097/00005053-200209000-00003
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- From clinical trial to prescription.Archives of General Psychiatry, 2002
- Improving Clinical TrialsArchives of General Psychiatry, 2002
- Clinical Profile of an Atypical Antipsychotic: RisperidoneSchizophrenia Bulletin, 2002
- The Effects of Olanzapine on the 5 Dimensions of Schizophrenia Derived by Factor AnalysisThe Journal of Clinical Psychiatry, 2001
- Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysisBMJ, 2000
- Conflicts of Interest in Biomedical ResearchJAMA, 2000
- Conflict of interest and the public trust.JAMA, 2000
- Uneasy Alliance — Clinical Investigators and the Pharmaceutical IndustryNew England Journal of Medicine, 2000
- Is Academic Medicine for Sale?New England Journal of Medicine, 2000
- SchizophreniaNew England Journal of Medicine, 1996